Abdul Khan, MD
Endocrinology, Diabetes & Metabolism · Hammond, LANPI 1902123995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $456,682 of the $587,404 with a category attached, or 77.7%. 43 manufacturers reported payments, led by Lilly USA, LLC at 35.1% of the total. Reporting peaked in 2022 at $148,872 and has fallen 70.5% since, to $43,863 in 2025. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,082 payments — averaging $542.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$206K
- Novo Nordisk$201K
- Sanofi-aventis U.S. LLC$121K
- Abbott$52K
- Merck$2K
- Medtronic$923
- plus $5K from 37 others
What the payments were for
- Consulting fees$12,8752%
- Speaking & faculty fees$456,68278%
- Travel & lodging$100,06617%
- Food & beverage$17,7633%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$151,921
- TRULICITY$81,374
- MOUNJARO$77,970
- SOLIQUA 100/33$76,137
- FREESTYLE LIBRE 3$50,170
- Ozempic$40,285
- TOUJEO$37,859
- TZIELD$15,878
- STEGLATRO$1,820
- iLet Bionic Pancreas$363
- FreeStyle Libre$134
- JARDIANCE$125
- ZEPBOUND$122
- iLet Insulin Infusion Kit Inset$121
- iLet Insulin Infusion Kit Contact Detach$121
- FreeStyle Libre 2$110
- BD NANO$101
How this compares
$587,404 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 427 | $502,509 |
| TrulicityDulaglutide | 369 | $398,618 |
| OzempicSemaglutide | 252 | $288,107 |
| JardianceEmpagliflozin | 266 | $212,806 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 187 | $167,185 |
| JanuviaSitagliptin Phosphate | 96 | $68,968 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $65,698 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $60,437 |
| Tresiba Flextouch U-100Insulin Degludec | 86 | $46,391 |
| FarxigaDapagliflozin Propanediol | 52 | $42,313 |
| Tresiba Flextouch U-200Insulin Degludec | 61 | $37,592 |
| RybelsusSemaglutide | 28 | $32,663 |
| Teriparatide | 11 | $31,654 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 230 | $26,885 |
| Novolog FlexpenInsulin Aspart | 127 | $21,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $206,270 | $909,013855 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $200,649 | $331,900329 claims |
| Boehringer IngelheimJardiance, Tradjenta | $335 | $227,919294 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog, Lantus | $120,753 | $177,889246 claims |
| MerckJanuvia, Janumet | $1,909 | $81,831117 claims |
| AstraZenecaFarxiga | $599 | $42,31352 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $636 | $13,18812 claims |
| AbbVieSynthroid | $379 | $6,50396 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $4,217734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Hammond
- Harold MillerHammond$73K
- Corey MajorsHammond$45K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.